A detailed history of Concourse Financial Group Securities, Inc. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 2,810 shares of GILD stock, worth $252,225. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,810
Previous 3,071 8.5%
Holding current value
$252,225
Previous $210,000 11.9%
% of portfolio
0.01%
Previous 0.01%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$66.59 - $83.99 $17,379 - $21,921
-261 Reduced 8.5%
2,810 $235,000
Q2 2024

Jul 23, 2024

SELL
$63.15 - $72.88 $76,537 - $88,330
-1,212 Reduced 28.3%
3,071 $210,000
Q1 2024

Apr 30, 2024

SELL
$71.58 - $87.29 $1.3 Million - $1.59 Million
-18,189 Reduced 80.94%
4,283 $313,000
Q4 2023

Feb 07, 2024

BUY
$73.27 - $83.09 $54,659 - $61,985
746 Added 3.43%
22,472 $1.82 Million
Q3 2023

Oct 25, 2023

BUY
$73.94 - $80.67 $5,027 - $5,485
68 Added 0.31%
21,726 $1.63 Million
Q2 2023

Aug 10, 2023

BUY
$76.01 - $86.7 $75,401 - $86,006
992 Added 4.8%
21,658 $1.67 Million
Q1 2023

May 15, 2023

BUY
$77.31 - $88.08 $247,392 - $281,856
3,200 Added 18.32%
20,666 $1.71 Million
Q4 2022

Jan 30, 2023

BUY
$62.32 - $89.47 $105,881 - $152,009
1,699 Added 10.78%
17,466 $0
Q3 2022

Nov 15, 2022

BUY
$59.54 - $68.01 $172,308 - $196,820
2,894 Added 22.48%
15,767 $973,000
Q2 2022

Aug 09, 2022

BUY
$57.72 - $65.01 $489,061 - $550,829
8,473 Added 192.57%
12,873 $796,000
Q1 2022

May 09, 2022

SELL
$57.92 - $72.58 $1.13 Million - $1.42 Million
-19,571 Reduced 81.64%
4,400 $262,000
Q4 2021

Feb 07, 2022

BUY
$64.88 - $73.64 $5,255 - $5,964
81 Added 0.34%
23,971 $1.74 Million
Q3 2021

Nov 09, 2021

BUY
$67.69 - $73.03 $42,103 - $45,424
622 Added 2.67%
23,890 $1.67 Million
Q2 2021

Aug 13, 2021

SELL
$63.47 - $69.35 $186,220 - $203,472
-2,934 Reduced 11.2%
23,268 $1.6 Million
Q1 2021

May 13, 2021

SELL
$60.0 - $68.46 $10,080 - $11,501
-168 Reduced 0.64%
26,202 $1.69 Million
Q4 2020

Feb 02, 2021

BUY
$56.65 - $64.55 $70,585 - $80,429
1,246 Added 4.96%
26,370 $1.54 Million
Q3 2020

Nov 13, 2020

BUY
$62.1 - $78.08 $156,678 - $196,995
2,523 Added 11.16%
25,124 $1.59 Million
Q2 2020

Aug 13, 2020

SELL
$72.34 - $84.0 $223,241 - $259,224
-3,086 Reduced 12.01%
22,601 $1.74 Million
Q1 2020

May 13, 2020

BUY
$62.63 - $80.22 $163,652 - $209,614
2,613 Added 11.32%
25,687 $1.92 Million
Q4 2019

Feb 14, 2020

BUY
$61.62 - $67.78 $948,948 - $1.04 Million
15,400 Added 200.68%
23,074 $1.5 Million
Q3 2019

Nov 13, 2019

SELL
$62.51 - $69.0 $1.07 Million - $1.18 Million
-17,129 Reduced 69.06%
7,674 $486,000
Q2 2019

Aug 13, 2019

SELL
$61.87 - $69.38 $8,104 - $9,088
-131 Reduced 0.53%
24,803 $1.68 Million
Q1 2019

May 15, 2019

SELL
$62.53 - $70.05 $49,148 - $55,059
-786 Reduced 3.06%
24,934 $1.62 Million
Q4 2018

Feb 14, 2019

BUY
$60.54 - $79.0 $723,695 - $944,366
11,954 Added 86.84%
25,720 $1.61 Million
Q3 2018

Nov 13, 2018

BUY
$71.28 - $78.92 $981,240 - $1.09 Million
13,766 New
13,766 $1.06 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $113B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.